Adenosine-Pathway Targeted Cancer Immunotherapy

Tuesday, May 10, 2022 - 09:00 to Thursday, May 12, 2022 - 15:30 (GMT-4)

Maximize the Clinical and Commercial Opportunity of the Adenosine-Pathway as a Second-generation Immuno-oncology Target.

Adenosine-pathway therapies have produced a plethora of promising clinical trial data that is being met with refreshed excitement, enthusiasm, and R and D investment for adenosine-pathway targets.

With reinvigorated confidence in the field, join fellow industry and academic thought leaders at the inaugural Adenosine-Pathway Targeted Cancer Immunotherapy Summit. This is the only comprehensive forum dedicated to optimizing efficacy of adenosine-pathway targeted drugs, overcoming challenges of resistance and immunosuppression and supercharging therapeutics to patients in need.

From analyzing the latest developments in understanding adenosine signaling in the TME, to rationalizing drug combinations that enhance patient responses, and exploring tools that quantify adenosine to select patients, this is the one-stop-shop event for all things adenosine-pathway.

Harness cutting-edge insights across 3 days of exclusive content from industry heavyweights including Astrazeneca, Takeda, Corvus Pharmaceuticals, iTeos Pharmaceuticals, Domain Therapeutics and more. Leave this definitive conference equipped with novel ideas, actionable lessons learned and new connections enabling you to progress your adenosine-pathway targeted cancer immunotherapies to the clinic.

Event Information

Hanson Wade
In-person - Omni Parker House 60 School Street Boston, MA 02108 United States
This event is under the auspices of UICC
Last update: 
Wednesday 26 January 2022